ArticleMedicine2025
Bibliometric analysis of sugammadex sodium literature based on the Web of Science database.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study employed bibliometric techniques to conduct both qualitative and quantitative analyses of literature pertaining to sugammadex sodium. The aim was to uncover the trends and hotspots of research in this field.
methodsPublications on sugammadex sodium published from January 2002 to December 2024 were extracted from the Web of Science Core Collection. Statistical analysis and visualization of publication data were performed using CiteSpace, Bibliometrix, and Excel.
resultsA total of 1006 articles were analyzed, including 3922 researchers from 56 countries/regions and 933 institutions. These studies have been published in 305 journals. Although Dutch scholars have demonstrated greater influence, the United States boasted the highest output. Among these institutions, Merck Germany had the highest publication volume and impact. Dutch researcher De Boer HD ranked the highest in terms of publication volume and influence. The British Journal of Anesthesia was the leading journal in terms of publications on sugammadex sodium, with a total of 59 articles. The most cited article in the field was by Kheterpal and colleagues, published in Anesthesiology in 2020. Keyword analysis revealed frequent comparisons of sugammadex sodium and neostigmine. Research hotspots have primarily focused on the reversal of rocuronium-induced neuromuscular blockade, deep neuromuscular blockade reversal, impact on residual neuromuscular blockade, and postoperative complications. The effects of sugammadex sodium on postoperative complications, particularly pulmonary complications, represent a current research frontier.
conclusionResearch on sugammadex sodium has received significant scholarly attention, with strong potential for future collaborative studies. The impact of sugammadex sodium on postoperative complications remains a promising area for in-depth analysis and a topic for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.